Consistent with higher PD‐L1 in chi‐G4S‐DR5 stable 4T1 tumors (Fig 5G), DR5 agonist and ROCK1 inhibitor co‐treatment (similar to MD5‐1‐ROCK1 co‐targeting) showed higher anti‐tumor efficacy (Fig 5H and I, tumors isolated after seven doses) as compared to lexatumumab alone. This evidence concerns the gene TNFRSF10B and neoplasm.